<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Adial Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/adial-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Adial Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 13:35:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/adial-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835429978dffbe2df0e159b.webp</url>
      <title>Adial Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-successfully-completes-manufacturing-of-demonstration-batch-production-enabling-clinical-and-registration-production-for-ad04-planned-phase-3-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-successfully-completes-manufacturing-of-demonstration-batch-production-enabling-clinical-and-registration-production-for-ad04-planned-phase-3-trial</guid>
      <pubDate>Wed, 22 Apr 2026 13:35:00 GMT</pubDate>
      <description>Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product productionGLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the successful comp</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-2025-fiscal-year-financial-results-and-provides-business-update-30</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-2025-fiscal-year-financial-results-and-provides-business-update-30</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-signs-an-exclusive-ad04-collaboration-framework-with-molteni-farmaceutici-for-europe-which-anticipates-nearly-dollar60-million-in-potential-royalties-and-milestones-upon-execution-of-a-definitive-agreement</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-signs-an-exclusive-ad04-collaboration-framework-with-molteni-farmaceutici-for-europe-which-anticipates-nearly-dollar60-million-in-potential-royalties-and-milestones-upon-execution-of-a-definitive-agreement</guid>
      <pubDate>Tue, 03 Mar 2026 13:17:00 GMT</pubDate>
      <description>The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 developmentGLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement wi</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-regains-full-compliance-with-nasdaq-listing-requirement</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-regains-full-compliance-with-nasdaq-listing-requirement</guid>
      <pubDate>Tue, 24 Feb 2026 14:00:00 GMT</pubDate>
      <description>Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requiremen</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-highlights-fda-policy-direction-that-may-reduce-pivotal-trial-burden-from-two-studies-to-one</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-highlights-fda-policy-direction-that-may-reduce-pivotal-trial-burden-from-two-studies-to-one</guid>
      <pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
      <description>Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today highlighted recent U.S. Food and Drug Administration (FDA) policy direction described by FDA Commissioner Martin A. Makar</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-present-oppenheimer-36th-140000230</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-present-oppenheimer-36th-140000230</guid>
      <pubDate>Tue, 17 Feb 2026 14:00:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, will be presenting at the Oppenheimer 36th Annual Healthcare Life Sciences Conference which will be held virtually February 25 - 26, 2026. Adial’s presentation is scheduled for Wednes</description>
    </item>
    <item>
      <title>Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-applauds-congressional-directive-advancing-143500721</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-applauds-congressional-directive-advancing-143500721</guid>
      <pubDate>Wed, 04 Feb 2026 14:35:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation inc</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-reverse-stock-210500436</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-reverse-stock-210500436</guid>
      <pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
      <description>Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026GLEN ALLEN, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (the “Reverse Split”) of its common stock, par value $0.001 per share (“Common Stock”), that</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-publication-international-140000411</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-publication-international-140000411</guid>
      <pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
      <description>New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and informationGLEN ALLEN, Va., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of the international patent application</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-warrant-inducement-130000798</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-announces-warrant-inducement-130000798</guid>
      <pubDate>Wed, 26 Nov 2025 13:00:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series C-1 Warrants (the &quot;Series C-1 Warrants&quot;) to purchase</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-third-quarter-133000385</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-third-quarter-133000385</guid>
      <pubDate>Fri, 14 Nov 2025 13:30:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We continue to achieve meaningful milestones on our path toward U.S. Food and</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-ceo-featured-guest-130000375</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-ceo-featured-guest-130000375</guid>
      <pubDate>Fri, 17 Oct 2025 13:00:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, was invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program. The show aired on Wednesday, October 15, 2025, and air</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-partners-genomind-precision-123000451</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-partners-genomind-precision-123000451</guid>
      <pubDate>Thu, 09 Oct 2025 12:30:00 GMT</pubDate>
      <description>Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 developmentGLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the an</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-provides-business-following-120000359</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-provides-business-following-120000359</guid>
      <pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
      <description>FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use DisorderGLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Ph</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-granted-180-calendar-123000601</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-granted-180-calendar-123000601</guid>
      <pubDate>Wed, 03 Sep 2025 12:30:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq&apos;s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-encouraged-u-senate-123000203</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-encouraged-u-senate-123000203</guid>
      <pubDate>Wed, 20 Aug 2025 12:30:00 GMT</pubDate>
      <description>U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory EnvironmentGLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded recent U.S. Senate legislative support for expanding clinical tria</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-second-quarter-123000112</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-reports-second-quarter-123000112</guid>
      <pubDate>Thu, 14 Aug 2025 12:30:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We believe we are at an inflection point in Adial’s journey. With the succes</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-completes-successful-eop2-120000814</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-completes-successful-eop2-120000814</guid>
      <pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
      <description>Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the completion of a successful End of Phase 2 meeting (EOP2M) with the</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-regains-compliance-nasdaq-123000489</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-regains-compliance-nasdaq-123000489</guid>
      <pubDate>Wed, 16 Jul 2025 12:30:00 GMT</pubDate>
      <description>GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders&apos; equity of at least $2,500,000</description>
    </item>
    <item>
      <title>Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045</title>
      <link>https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-files-pct-patent-123000932</link>
      <guid isPermaLink="true">https://6ix.com/company/adial-pharmaceuticals-inc/news/adial-pharmaceuticals-files-pct-patent-123000932</guid>
      <pubDate>Wed, 09 Jul 2025 12:30:00 GMT</pubDate>
      <description>Application Update Based on Extensive Review of DataGLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the filing of an update to the provisional patent application for AD04 which was filed in July 2024, the Company’s lead investigational genetically targeted, serotonin-3 re</description>
    </item>
  </channel>
</rss>